Gaucher disease market to reach $1.3 billion across 7MM in 2032

The market for Gaucher disease, a rare inherited metabolic disorder characterized by hepatosplenomegaly, bone disease, and anemia, is set to experience a compound annual growth rate (CAGR) of 0.79% across the seven major markets (7MM: The USA, German, Italy, Spain, UK, and Israel) from $1.2 billion in 2022 to $1.3 billion in 2032.

Pharma analytics firm GlobalData’s latest report, “Gaucher Disease: Opportunity Assessment and Forecast”, reveals improved testing approaches, increased diagnosis, and the launch of venglustat malate, under development at French pharma major Sanofi (Euronext: SAN), will be the main drivers of steady market growth over the forecast period.

“Improvements in diagnostic approaches, particularly by increased inclusion of Gaucher disease in screening panels, as well as increased patient numbers in line with population growth, will increase market size in the next decade. Additionally, market growth will be further enhanced by venglustat malate, which GlobalData anticipates will launch in the US and 5EU markets during the forecast period,” commented GlobalData’s pharma analyst Sulayman Patel.